Clinical Trial Update: Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) [Phase 2]

View source ↗

Summary

Phase II study of imatinib plus hydroxyurea in patients with recurrent or progressive grade II low-grade glioma; trial completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Low-grade Glioma

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Imatinib (imatinib)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-03-15